Energy research: MOTS-c in mice, and what an NAD precursor trial did not show

"Energy" and "longevity" are the words on the label. The papers underneath are narrower. One is a mitochondrial peptide in mice. The other is a human trial of an oral precursor that moved a blood measurement and did not establish a change in how people feel or function.

MOTS-c in mice

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Lee and colleagues, in Cell Metabolism in 2015, described it as a metabolic signal whose main target looks like skeletal muscle, via AMPK. In their mouse experiments, treatment was associated with better insulin-stimulated glucose handling. In high-fat-diet experiments, treated mice were reported not to gain the same weight as controls, without a difference in calories eaten, and liver fat staining was lower. In older mice, a short course was associated with insulin-stimulated glucose uptake in muscle closer to that of younger mice. Group sizes in the figures are small, on the order of six to ten animals. The work is why researchers study MOTS-c for metabolic flexibility. It is not a human energy trial, and it is not evidence that a person will feel less tired.

NAD in the blood is not the same as energy in a person

NAD+ is a coenzyme in cellular energy metabolism. Levels of NAD-related metabolites are reported to fall with age in several tissues, which is why the topic attracts longevity research. Most of the human supplementation trials use an oral precursor, such as nicotinamide riboside, not an injected NAD+ preparation.

Martens and colleagues, in Nature Communications in 2018, ran a six-week randomised crossover in healthy adults aged 55 to 79. Thirty people were randomised and 24 finished. Oral nicotinamide riboside raised NAD+ in blood cells compared with placebo. That is a positive biochemical result. Exploratory measures of blood pressure and arterial stiffness did not hold up as clear effects once multiple comparisons were accounted for. The trial did not show a change in resting metabolic rate that you could treat as "more energy." Raising a blood NAD marker for six weeks, in already healthy people, using a capsule, does not tell you what an NAD+ research pen would do.

How to hold both results

The mouse paper is allowed to be positive about insulin sensitivity and diet-induced weight gain in mice. The human precursor paper is mixed: a blood marker moved, and the functional hints did not clear the statistical bar the authors set. Neither result is a reason to expect better stamina, and neither is a dose. If a later human study of MOTS-c or of NAD+ itself is null, it will be written up the same way.

The library notes are MOTS-c and NAD+. The briefing carries the next papers, including the ones that do not move.